Stock Ratings / Health Care / EXOZ / financials

ELUT (34) INMB (45) IMA (24) ESLA (41) ⌘ Pro Terminal →

eXoZymes Inc. (EXOZ) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$4.11 -2.72% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.08

eXoZymes Inc. (EXOZ) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $38.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.08 (-0.68%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EXOZ)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY EXOZ SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$5.25-22.1% Next Q

Q2 (-2Q)

Grade D$4.09-2.2% Next Q

Q3 (-1Q)

Grade E$4.00+2.8% Next Q

Current

Grade D-$4.11-8.3% Hist 90D α

Trajectory: D (44) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a EXOZ Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While EXOZ currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.68) and Max Pain ($4.32) forces dealer call-delta covering toward $19.32.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EXOZ• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “EXOZ Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How EXOZ Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $70.1K

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-0.2%	-$9.2M	-$6.7M	-45%
FY 2024	$4.00B	52%	-0.1%	-$5.9M	-$8.9M	-45%
FY 2023	$70.1K	52%	-80%	-$2.0M	-$1.2M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EXOZ)

✓Walkthrough of EXOZ's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EXOZ // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -58.82%▼ DESCENDING CHANNEL

2026-10-30O $4.18H $4.19L $4.01C $4.11VOL 6.1K

RES: $5.47SUP: $3.19SMA50: $5.68SMA200: $7.77

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EXOZ Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EXOZ Butterfly Map → + Track EXOZ →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EXOZ today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EXOZ. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EXOZ today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EXOZ)

Health Care Rank #792 of 1016 ⚔️ ELUT vs EXOZ Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EXOZ vs. ELUT, INMB, IMA, ESLA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, eXoZymes Inc. (EXOZ) ranks #792 by composite RQD confidence (36/100, grade D-) and #780 by equity capitalization ($38.2M). Within this direct 5-issuer industry benchmark cohort, EXOZ leads on earnings valuation at N/A trailing P/E, while EXOZ leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. INMB currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with EXOZ at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EXOZ ACTIVE eXoZymes Inc.	D-	36/100	—	—	-35.0%	-2.72%	$38.2M	Benchmark Subject
ELUT Elutia Inc. (Class A)	E	34/100	—	53.7%	-35.0%	-3.13%	$36.0M	/elut-vs-exoz →
INMB INmune Bio Inc.	D	45/100	—	—	-35.0%	+4.58%	$44.4M	/inmb-vs-exoz →
IMA ImageneBio Inc.	E	24/100	—	—	-35.0%	-3.57%	$46.0M	/ima-vs-exoz →
ESLA Estrella Immunopharma Inc.	D-	41/100	—	—	-35.0%	-11.32%	$31.7M	/esla-vs-exoz →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002010788

In its most recent audited fiscal period (FY2025, filed 2025-12-31), eXoZymes Inc. (EXOZ) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$9.2M, operating cash flow of -$6.5M, and free cash flow of -$6.7M (+25.1% YoY). On the balance sheet, EXOZ closed FY2025 with $6.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$9.2M	-$6.5M	-$6.7M	$6.0M	—
FY2024 (FY)	2024-12-31	$0	-$5.9M	-$8.5M	-$8.9M	$13.0M	—
FY2023 (FY)	2023-12-31	$70.1K	-$2.0M	-$1.2M	-$1.2M	—	—

3. EXOZ Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EXOZ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, eXoZymes Inc. (NASDAQ: EXOZ) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $4.11 (-2.72% 1D, market cap $38.2M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EXOZ ranks #792 in composite RQD confidence.

How does EXOZ compare to ELUT and INMB in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EXOZ carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ELUT (Elutia Inc. (Class A)) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $36.0M) and INMB (INmune Bio Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $44.4M). Among the 5-stock peer group, EXOZ leads on earnings multiple (N/A) while EXOZ leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EXOZ?

Per EXOZ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002010788), eXoZymes Inc. generated $0 in revenue, -$9.2M in net income, and -$6.7M in free cash flow against $6.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EXOZ trading relative to its 50-day, 200-day, and 52-week technical levels?

EXOZ last traded at $4.11 (-2.72% on volume of 9,234 shares), positioning the stock -27.64% below its 50-day simple moving average ($5.68) and -47.10% below its 200-day simple moving average ($7.77). Across its 52-week range of $3.24 to $18.40, EXOZ sits at the 5.7% percentile with a 14-day RSI of 36.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.60 to $4.62).